ALCL was first described in 1985 based according to its unique characteristic of cohesive proliferation of large pleomorphic cells expressing CD 30 (Ki-1).[6] ALK+ ALCL has a more variable presentation but distinct phenotype. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.